These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

433 related articles for article (PubMed ID: 33228395)

  • 1. Inhibition of Cholesteryl Ester Transfer Protein Preserves High-Density Lipoprotein Cholesterol and Improves Survival in Sepsis.
    Trinder M; Wang Y; Madsen CM; Ponomarev T; Bohunek L; Daisely BA; Julia Kong H; Blauw LL; Nordestgaard BG; Tybjærg-Hansen A; Wurfel MM; Russell JA; Walley KR; Rensen PCN; Boyd JH; Brunham LR
    Circulation; 2021 Mar; 143(9):921-934. PubMed ID: 33228395
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anacetrapib, but not evacetrapib, impairs endothelial function in CETP-transgenic mice in spite of marked HDL-C increase.
    Simic B; Mocharla P; Crucet M; Osto E; Kratzer A; Stivala S; Kühnast S; Speer T; Doycheva P; Princen HM; van der Hoorn JW; Jukema JW; Giral H; Tailleux A; Landmesser U; Staels B; Lüscher TF
    Atherosclerosis; 2017 Feb; 257():186-194. PubMed ID: 28152406
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cholesteryl Ester Transfer Protein Inhibition With Anacetrapib Decreases Fractional Clearance Rates of High-Density Lipoprotein Apolipoprotein A-I and Plasma Cholesteryl Ester Transfer Protein.
    Reyes-Soffer G; Millar JS; Ngai C; Jumes P; Coromilas E; Asztalos B; Johnson-Levonas AO; Wagner JA; Donovan DS; Karmally W; Ramakrishnan R; Holleran S; Thomas T; Dunbar RL; deGoma EM; Rafeek H; Baer AL; Liu Y; Lassman ME; Gutstein DE; Rader DJ; Ginsberg HN
    Arterioscler Thromb Vasc Biol; 2016 May; 36(5):994-1002. PubMed ID: 26966279
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Future of cholesteryl ester transfer protein (CETP) inhibitors: a pharmacological perspective.
    Mohammadpour AH; Akhlaghi F
    Clin Pharmacokinet; 2013 Aug; 52(8):615-26. PubMed ID: 23658137
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increasing HDL levels by inhibiting cholesteryl ester transfer protein activity in rabbits with hindlimb ischemia is associated with increased angiogenesis.
    Wu BJ; Shrestha S; Ong KL; Johns D; Dunn LL; Hou L; Barter PJ; Rye KA
    Int J Cardiol; 2015 Nov; 199():204-12. PubMed ID: 26204569
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cholesteryl Ester Transfer Protein Influences High-Density Lipoprotein Levels and Survival in Sepsis.
    Trinder M; Genga KR; Kong HJ; Blauw LL; Lo C; Li X; Cirstea M; Wang Y; Rensen PCN; Russell JA; Walley KR; Boyd JH; Brunham LR
    Am J Respir Crit Care Med; 2019 Apr; 199(7):854-862. PubMed ID: 30321485
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antisense oligonucleotide inhibition of cholesteryl ester transfer protein enhances RCT in hyperlipidemic, CETP transgenic, LDLr-/- mice.
    Bell TA; Graham MJ; Lee RG; Mullick AE; Fu W; Norris D; Crooke RM
    J Lipid Res; 2013 Oct; 54(10):2647-57. PubMed ID: 23801661
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cholesteryl ester transfer-protein modulator and inhibitors and their potential for the treatment of cardiovascular diseases.
    Shinkai H
    Vasc Health Risk Manag; 2012; 8():323-31. PubMed ID: 22661899
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of anacetrapib on plasma lipids in specific patient subgroups in the DEFINE (Determining the Efficacy and Tolerability of CETP INhibition with AnacEtrapib) trial.
    Brinton EA; Kher U; Shah S; Cannon CP; Davidson M; Gotto AM; Ashraf TB; McCrary Sisk C; Dansky H; Mitchel Y; Barter P;
    J Clin Lipidol; 2015; 9(1):65-71. PubMed ID: 25670362
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CETP inhibition enhances monocyte activation and bacterial clearance and reduces streptococcus pneumonia-associated mortality in mice.
    Deng H; Liang WY; Chen LQ; Yuen TH; Sahin B; Vasilescu DM; Trinder M; Walley K; Rensen PCN; Boyd JH; Brunham LR
    JCI Insight; 2024 Apr; 9(8):. PubMed ID: 38646937
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anacetrapib: hope for CETP inhibitors?
    Gurfinkel R; Joy TR
    Cardiovasc Ther; 2011 Oct; 29(5):327-39. PubMed ID: 20406242
    [TBL] [Abstract][Full Text] [Related]  

  • 12. On- and off-target pharmacology of torcetrapib: current understanding and implications for the structure activity relationships (SAR), discovery and development of cholesteryl ester-transfer protein (CETP) inhibitors.
    Johns DG; Duffy J; Fisher T; Hubbard BK; Forrest MJ
    Drugs; 2012 Mar; 72(4):491-507. PubMed ID: 22356288
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anacetrapib reduces (V)LDL cholesterol by inhibition of CETP activity and reduction of plasma PCSK9.
    van der Tuin SJ; Kühnast S; Berbée JF; Verschuren L; Pieterman EJ; Havekes LM; van der Hoorn JW; Rensen PC; Jukema JW; Princen HM; Willems van Dijk K; Wang Y
    J Lipid Res; 2015 Nov; 56(11):2085-93. PubMed ID: 26342106
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anacetrapib for the treatment of dyslipidaemia: the last bastion of the cholesteryl ester transfer protein inhibitors?
    Page MM; Hooper AJ; Burnett JR
    Expert Opin Pharmacother; 2016; 17(2):275-81. PubMed ID: 26642232
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of cholesteryl ester transfer protein increases cholesteryl ester content of large HDL independently of HDL-to-HDL homotypic transfer: in vitro vs in vivo comparison using anacetrapib and dalcetrapib.
    Johns DG; Chen Y; Wang SP; Castro-Perez J; Previs SF; Roddy TP
    Eur J Pharmacol; 2015 Sep; 762():256-62. PubMed ID: 26049012
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cholesteryl ester transfer protein inhibitors in precision medicine.
    Su X; Li G; Deng Y; Chang D
    Clin Chim Acta; 2020 Nov; 510():733-740. PubMed ID: 32941836
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CETP Inhibition Improves HDL Function but Leads to Fatty Liver and Insulin Resistance in CETP-Expressing Transgenic Mice on a High-Fat Diet.
    Zhu L; Luu T; Emfinger CH; Parks BA; Shi J; Trefts E; Zeng F; Kuklenyik Z; Harris RC; Wasserman DH; Fazio S; Stafford JM
    Diabetes; 2018 Dec; 67(12):2494-2506. PubMed ID: 30213825
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patient considerations and clinical impact of cholesteryl ester transfer protein inhibitors in the management of dyslipidemia: focus on anacetrapib.
    Miyares MA; Davis K
    Vasc Health Risk Manag; 2012; 8():483-93. PubMed ID: 22977305
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CETP (Cholesteryl Ester Transfer Protein) Inhibition With Anacetrapib Decreases Production of Lipoprotein(a) in Mildly Hypercholesterolemic Subjects.
    Thomas T; Zhou H; Karmally W; Ramakrishnan R; Holleran S; Liu Y; Jumes P; Wagner JA; Hubbard B; Previs SF; Roddy T; Johnson-Levonas AO; Gutstein DE; Marcovina SM; Rader DJ; Ginsberg HN; Millar JS; Reyes-Soffer G
    Arterioscler Thromb Vasc Biol; 2017 Sep; 37(9):1770-1775. PubMed ID: 28729361
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Common variation in cholesteryl ester transfer protein: relationship of first major adverse cardiovascular events with the apolipoprotein B/apolipoprotein A-I ratio and the total cholesterol/high-density lipoprotein cholesterol ratio.
    Kappelle PJ; Gansevoort RT; Hillege HJ; Wolffenbuttel BH; Dullaart RP;
    J Clin Lipidol; 2013; 7(1):56-64. PubMed ID: 23351584
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.